HRMY FY2024 EPS Estimate Raised by Cantor Fitzgerald

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Tuesday, February 11th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of $2.55 per share for the year, up from their prior estimate of $2.53. Cantor Fitzgerald currently has a "Overweight" rating and a $58.00 target price on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. Cantor Fitzgerald also issued estimates for Harmony Biosciences' FY2025 earnings at $3.49 EPS.

HRMY has been the subject of a number of other research reports. Needham & Company LLC reissued a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday, January 27th. Oppenheimer reaffirmed an "outperform" rating and set a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday. They set a "buy" rating and a $55.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $55.00.

Harmony Biosciences Trading Down 0.3 %

Shares of NASDAQ HRMY traded down $0.10 during midday trading on Wednesday, reaching $38.98. The company had a trading volume of 415,183 shares, compared to its average volume of 549,012. Harmony Biosciences has a one year low of $28.14 and a one year high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The firm's fifty day moving average price is $36.06 and its 200-day moving average price is $35.60. The stock has a market cap of $2.22 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80.

Institutional Trading of Harmony Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after buying an additional 436 shares during the last quarter. Mendota Financial Group LLC grew its stake in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock worth $33,000 after buying an additional 965 shares during the last quarter. CWM LLC grew its stake in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company's stock worth $59,000 after buying an additional 775 shares during the last quarter. KBC Group NV grew its stake in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after buying an additional 819 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Harmony Biosciences during the 3rd quarter valued at $74,000. Hedge funds and other institutional investors own 86.23% of the company's stock.

Insider Transactions at Harmony Biosciences

In related news, CEO Jeffrey M. Dayno sold 19,293 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey Dierks sold 10,507 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total value of $388,864.07. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,452 shares of company stock valued at $2,831,679. Corporate insiders own 30.80% of the company's stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.